Diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP) is challenging due to its variable presentations, overlapping conditions, and difficulties in interpreting electrodiagnostic results. The 2021 guidelines from the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) introduced criteria for Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) variants and incorporated sensory abnormalities into diagnostic standards.

CIDP management involves personalized treatment with intravenous immunoglobulin (IVIg), corticosteroids, or plasma exchange, tailored to each patient’s needs. Evaluating treatment responses using disability and impairment scales ensures timely adjustments, preventing overtreatment or misdiagnosis. Although many patients respond to first-line treatments, some cases require further diagnostic review if improvement is lacking. Future research aims to refine diagnostic tools, explore autoantibody-based tests, and adopt a broader approach to autoimmune neuropathies, treating CIDP as part of this spectrum. Consistent outcome measures remain key to optimizing care and improving patient outcomes.

Reference: van Doorn IN, Eftimov F, Wieske L, van Schaik IN, Verhamme C. Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives. Ther Clin Risk Manag. 2024 Feb 14;20:111-126. doi: 10.2147/TCRM.S360249. PMID: 38375075; PMCID: PMC10875175.